XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2135 SEK | -1.39% |
|
-39.35% | -97.86% |
| Apr. 22 | Transcript : Xbrane Biopharma AB - Special Call | |
| Mar. 18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
Presentation Operator MessageOperator (Operator)Welcome to the Xbrane Biopharma Q4 report pres...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
2024-05-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2135
SEK
Average target price
0.625
SEK
Spread / Average Target
+192.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.86% | 29.78M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024
